XSHG
603990
Market cap868mUSD
Oct 09, Last price
19.40CNY
1D
1.84%
1Q
-4.20%
Jan 2017
8.38%
IPO
288.78%
Name
Suzhou MedicalSystem Technology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Suzhou MedicalSystem Technology Co., Ltd., established in Suzhou, China, in 2005, is a company dedicated to developing and implementing advanced clinical information technology and digital hospital management solutions throughout China. Their product portfolio primarily features the "DoCare" suite of systems: The DoCare anesthesia clinical information system is tailored for the perioperative environment, offering an integrated platform that streamlines, digitalizes, automates, and intelligently manages clinical workflows during surgical procedures. The DoCare intensive auxiliary diagnosis clinical information system focuses on extracting and scientifically analyzing treatment data from ICU patients. It integrates diverse medical information, including treatment details, inspection results, nursing records, and doctor's orders, to support diagnosis and decision-making. The DoCare operative medical behavior management system provides intelligent oversight for operating room resources and staff activities. The DoCare emergency clinical information system offers comprehensive management for emergency care services. This spans the entire patient journey, from pre-hospital first aid and initial triage to active rescue, emergency observation, specialized emergency operating rooms and ICUs, and final patient outcomes. The DoCare pre-hospital first aid clinical information system creates a unified digital service platform connecting emergency command centers, medical personnel (doctors, nurses, visiting staff), and patients for pre-hospital care. Beyond these core offerings, the company also provides specialized "smart" solutions for operating theaters (OT), intensive care units (ICUs), and emergency departments. Additionally, their smart specialty solutions include systems for laminar airflow rooms, clinical pathways, mobile nursing information, and central sterile supply department (CSSD) management.
Key people
Wangsheng Wu
Chief Financial Officer
Zejiang Chen
Deputy General Manager, Director
Zhiyuan Xu
Deputy General Manager
Shichen Peng
Director
Director
Pingwen Xu
Independent Director
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||